The role of tumour immunity in response to ET has been mainly studied in ER+/HER2- BC disease, with higher expression of genes involved in immune enrichment and targetable immune checkpoint components being correlated with higher risk such as Luminal B tumours.24 This evidence concerns the gene ERBB2 and neoplasm.